Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Freed From Pfizer, Capsugel May Find More Market Opportunities

This article was originally published in The Tan Sheet

Executive Summary

Pfizer's divestiture of Capsugel moves the gelatin capsule manufacturer out from under pharma ownership, potentially opening a door to more business.
Advertisement

Related Content

Private Equity Reinvents Its Take On Biopharma
Novartis Seems Close to Consumer Health Sale – Analyst
Novartis Seems Close to Consumer Health Sale – Analyst
Pfizer Likes Consumer Business Fit As Segment Grows 8%
Consumer Division Divestments Would Spotlight Firms’ Value – Analysts
Pfizer CEO Read Expects Gradual Plans For Change In Second Half 2011
Pfizer Nutrition Continues Launches Despite Divestment Possibility
GlaxoSmithKline's OTC Garage Sale Includes alli, FiberChoice
Sales & Earnings In Brief
After Negative FDA Committee Vote, Jazz Has Few Notes To Play Beyond Fibromyalgia

Topics

Advertisement
UsernamePublicRestriction

Register

PS104978

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel